Business brief
Corporate Transformations and Tech Frontiers
Israeli titans Teva and Check Point retool core businesses as quantum partner Qedma sets industrial benchmarks.
Business
Check Point's core firewall franchise is no longer driving growth — forcing a painful sales overhaul to defend its base against cloud-native rivals.
BackgroundCheck Point invented the stateful inspection firewall and dominated perimeter network defense for decades. Under former 8200 commander Nadav Zafrir, the company is attempting to shift its traditional installed enterprise base into cloud security platforms.
- Check Point's 23% stock drop in 2026 contrasts with double-digit rallies at cloud rivals Palo Alto Networks and CrowdStrike, widening a market valuation gap.
- UBS maintained a Neutral rating with a $135 price target, pointing to steady cash flow from enterprise renewals despite ongoing top-line growth headwinds.
- Zafrir is overhauling global sales operations to prioritize integrated AI threat prevention platforms over traditional physical network security appliances.
Business
Qedma's error-mitigation software unlocked practical quantum advantage on existing hardware — bringing commercial quantum simulation years closer to market viability.
BackgroundQuantum error mitigation suppresses physical hardware noise, allowing current noisy processors to execute complex algorithms reliably. This software layer serves as an essential stepping stone before fully fault-tolerant quantum computers are commercially built.
- The combined system successfully modeled physical interactions that would stall classical supercomputers running 700,000 processing cores, proving functional utility for hardware available today.
- Qedma's error-mitigation algorithms work by isolating operational environmental noise without adding heavy physical qubit overhead to quantum hardware circuits.
- The benchmark offers commercial proof that hybrid quantum-classical software can accelerate practical research across advanced material science and chemistry.
Business
Teva's shift toward high-margin branded drugs is generating real sales growth — putting its long recovery from generic price erosion on firm footing.
BackgroundTeva's multi-year pivot strategy depends on expanding proprietary brand-name drugs like Austedo and Ajovy to rebuild margins. That revenue growth is designed to offset severe generic price erosion and past legal liability settlements.
- Quarterly revenue across key branded treatments Austedo, Ajovy, and Uzedy topped $1 billion for the first time, validating the company's shift away from low-margin generics.
- Teva logged a GAAP net loss of $576 million driven by $726 million in research charges tied to its recent acquisition of Emalex Biosciences.
- Management plans to transition Teva's American Depositary Shares into a direct New York Stock Exchange equity listing by September to broaden institutional investor access.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.